Thrombotic thrombocytopenic purpura: Difference between revisions
Jump to navigation
Jump to search
imported>Robert Badgett No edit summary |
imported>Robert Badgett No edit summary |
||
| Line 2: | Line 2: | ||
In [[medicine]] and [[hematology]], '''thrombotic thrombocytopenic purpura''' ('''TTP''') is "an acquired, congenital, or familial disorder caused by [[platelet aggregation]] with [[thrombosis]] in terminal arterioles and capillaries. Clinical features include [[thrombocytopenia]]; [[hemolytic anemia]]; [[azotemia]]; [[fever]]; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as [[renal failure]]."<ref>{{MeSH}}</ref> | In [[medicine]] and [[hematology]], '''thrombotic thrombocytopenic purpura''' ('''TTP''') is "an acquired, congenital, or familial disorder caused by [[platelet aggregation]] with [[thrombosis]] in terminal arterioles and capillaries. Clinical features include [[thrombocytopenia]]; [[hemolytic anemia]]; [[azotemia]]; [[fever]]; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as [[renal failure]]."<ref>{{MeSH}}</ref> | ||
Patients with primary TTP may have low von Willebrand factor-degrading protease (ADAMTS13 protein), an [[ADAM Protein]].<ref name="pmid20032506">{{cite journal| author=Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN| title=Survival and relapse in patients with thrombotic thrombocytopenic purpura. | journal=Blood | year= 2010 | volume= 115 | issue= 8 | pages= 1500-11; quiz 1662 | pmid=20032506 | ==Etiology/cause== | ||
| url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20032506 | doi=10.1182/blood-2009-09-243790 }} </ref> This deficiency allows thrombi due to von Willebrand | Patients with primary TTP may have low von Willebrand factor-degrading protease (ADAMTS13 protein), an [[ADAM Protein]].<ref name="pmid20032506">{{cite journal| author=Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN| title=Survival and relapse in patients with thrombotic thrombocytopenic purpura. | journal=Blood | year= 2010 | volume= 115 | issue= 8 | pages= 1500-11; quiz 1662 | pmid=20032506 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=clinical.uthscsa.edu/cite&retmode=ref&cmd=prlinks&id=20032506 | doi=10.1182/blood-2009-09-243790 }} </ref> This deficiency allows thrombi due to [[von Willebrand Factor]] (vWF) | ||
==Diagnosis== | |||
In the Oklahoma registry, 23% (60/261) patients with idiopathic thrombotic thrombocytopenic purpura had ADAMTS13 activity of less than 10%.<ref name="pmid20032506">{{cite journal| author=Kremer Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN| title=Survival and relapse in patients with thrombotic thrombocytopenic purpura. | journal=Blood | year= 2010 | volume= 115 | issue= 8 | pages= 1500-11; quiz 1662 | pmid=20032506 | doi=10.1182/blood-2009-09-243790 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20032506 }} </ref><ref name="pmid12637323">{{cite journal| author=Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA et al.| title=ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. | journal=Blood | year= 2003 | volume= 102 | issue= 1 | pages= 60-8 | pmid=12637323 | doi=10.1182/blood-2003-01-0193 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12637323 }} </ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 20:03, 25 September 2013
In medicine and hematology, thrombotic thrombocytopenic purpura (TTP) is "an acquired, congenital, or familial disorder caused by platelet aggregation with thrombosis in terminal arterioles and capillaries. Clinical features include thrombocytopenia; hemolytic anemia; azotemia; fever; and thrombotic microangiopathy. The classical form also includes neurological symptoms and end-organ damage, such as renal failure."[1]
Etiology/cause
Patients with primary TTP may have low von Willebrand factor-degrading protease (ADAMTS13 protein), an ADAM Protein.[2] This deficiency allows thrombi due to von Willebrand Factor (vWF)
Diagnosis
In the Oklahoma registry, 23% (60/261) patients with idiopathic thrombotic thrombocytopenic purpura had ADAMTS13 activity of less than 10%.[2][3]
References
- ↑ Anonymous (2025), Thrombotic thrombocytopenic purpura (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ 2.0 2.1 Hovinga JA, Vesely SK, Terrell DR, Lämmle B, George JN (2010). "Survival and relapse in patients with thrombotic thrombocytopenic purpura.". Blood 115 (8): 1500-11; quiz 1662. DOI:10.1182/blood-2009-09-243790. PMID 20032506. Research Blogging.
Cite error: Invalid
<ref>tag; name "pmid20032506" defined multiple times with different content - ↑ Vesely SK, George JN, Lämmle B, Studt JD, Alberio L, El-Harake MA et al. (2003). "ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.". Blood 102 (1): 60-8. DOI:10.1182/blood-2003-01-0193. PMID 12637323. Research Blogging.